ES2389611T3 - Vacuna contra la gripe humana que contiene cuatro péptidos de influenza - Google Patents

Vacuna contra la gripe humana que contiene cuatro péptidos de influenza Download PDF

Info

Publication number
ES2389611T3
ES2389611T3 ES10003160T ES10003160T ES2389611T3 ES 2389611 T3 ES2389611 T3 ES 2389611T3 ES 10003160 T ES10003160 T ES 10003160T ES 10003160 T ES10003160 T ES 10003160T ES 2389611 T3 ES2389611 T3 ES 2389611T3
Authority
ES
Spain
Prior art keywords
human
influenza
epitope
epitopes
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10003160T
Other languages
English (en)
Spanish (es)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Raphael Levi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2389611T3 publication Critical patent/ES2389611T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES10003160T 1998-11-30 1999-11-28 Vacuna contra la gripe humana que contiene cuatro péptidos de influenza Expired - Lifetime ES2389611T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
IL12733198 1998-11-30

Publications (1)

Publication Number Publication Date
ES2389611T3 true ES2389611T3 (es) 2012-10-29

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10003160T Expired - Lifetime ES2389611T3 (es) 1998-11-30 1999-11-28 Vacuna contra la gripe humana que contiene cuatro péptidos de influenza

Country Status (15)

Country Link
US (3) US6740325B1 (cg-RX-API-DMAC7.html)
EP (2) EP1135159A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002531415A (cg-RX-API-DMAC7.html)
KR (1) KR100703571B1 (cg-RX-API-DMAC7.html)
AT (1) ATE556719T1 (cg-RX-API-DMAC7.html)
AU (1) AU766883B2 (cg-RX-API-DMAC7.html)
BR (1) BR9915811A (cg-RX-API-DMAC7.html)
CA (1) CA2352454C (cg-RX-API-DMAC7.html)
DK (1) DK2204187T3 (cg-RX-API-DMAC7.html)
ES (1) ES2389611T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040620A1 (cg-RX-API-DMAC7.html)
IL (3) IL127331A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ511918A (cg-RX-API-DMAC7.html)
PT (1) PT2204187E (cg-RX-API-DMAC7.html)
WO (1) WO2000032228A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2002026252A1 (en) * 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US20090169576A1 (en) * 2005-10-26 2009-07-02 Roberto Crea Influenza combinatorial antigen vaccine
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DK1968632T3 (da) 2005-12-06 2012-07-16 Yeda Res & Dev Forbedret influenzavaccine
PL2478916T3 (pl) * 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840997A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
CA2840937A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961700A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
CA2840941A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
EP3189852B1 (en) 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
WO2017022793A1 (ja) 2015-08-06 2017-02-09 日東電工株式会社 免疫誘導促進組成物及びワクチン医薬組成物
BR112019013402A2 (pt) * 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
WO2026101847A1 (en) 2024-11-05 2026-05-15 Bluewillow Biologics, Inc. Methods of influenza vaccination and compositions for the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
IL143367A (en) 2006-09-05
HK1040620A1 (zh) 2002-06-21
HK1145448A1 (en) 2011-04-21
KR20010089512A (ko) 2001-10-06
ATE556719T1 (de) 2012-05-15
NZ511918A (en) 2003-08-29
AU1406600A (en) 2000-06-19
PT2204187E (pt) 2012-08-10
US7514086B2 (en) 2009-04-07
AU766883B2 (en) 2003-10-23
CA2352454A1 (en) 2000-06-08
EP2204187B1 (en) 2012-05-09
WO2000032228A3 (en) 2000-10-05
EP2204187A1 (en) 2010-07-07
JP2002531415A (ja) 2002-09-24
US20050002954A1 (en) 2005-01-06
US20070122424A1 (en) 2007-05-31
IL143367A0 (en) 2002-04-21
US6740325B1 (en) 2004-05-25
CA2352454C (en) 2013-02-05
BR9915811A (pt) 2001-08-21
IL127331A0 (en) 1999-09-22
US7192595B2 (en) 2007-03-20
EP1135159A2 (en) 2001-09-26
KR100703571B1 (ko) 2007-04-05
DK2204187T3 (da) 2012-08-20
WO2000032228A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
AU766883B2 (en) Peptide-based vaccine for influenza
Ben-Yedidia et al. Towards an epitope-based human vaccine for influenza
Ben-Yedidia et al. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection
Khanna et al. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development
Levi et al. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection
Jeon et al. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus
Haynes et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge
ES2385842T3 (es) Vacuna mejorada contra la gripe
Biswas et al. Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines: flu vaccine efficacy encounters significant hurdles from pre-existing immunity of the host suggesting assessment of host immunity before vaccination
US20090104228A1 (en) Influenza Virus Vaccine
Wang et al. Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
WO2016198642A1 (en) Live recombinant measles-m2 virus - its use in eliciting immunity against influenza viruses
Music et al. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets
US12397050B2 (en) Universal mammalian influenza vaccine
Gasparini et al. Live attenuated influenza vaccine–a review
Zhang et al. Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses
Katz et al. Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains.
KR102103638B1 (ko) 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신
Zhang Intranasal Administration of Highly Conserved Influenza Antigens to Elicit Local Mucosal Responses and Enhance Cross-Subtype Protection
HK1145448B (en) Human flu vaccine containing four influenza peptides
MXPA01005398A (en) Peptide-based vaccine for influenza
Ben-Yedidia et al. Synthetic peptide-based vaccines against influenza
Ben-Yedidia A peptide-based vaccine against influenza
Arnon Development of Synthetic Vaccines
Shortridge et al. Avirulent Avian Influenza Virus as